MONTREAL, Dec. 13 (UPI) -- A McGill University study suggests a new anti-depressant drug works by raising levels of endocannabinoids -- similar to a
substance found in marijuana.
The study suggests the new drug, called URB597, might represent a safer alternative to use of marijuana for treatment of pain and depression, and open
the door to new and improved treatments for clinical depression.
In pre-clinical laboratory tests researchers found URB597 increased the production of endocannabinoids by blocking their degradation, resulting in
measurable antidepressant effects.
Seems like it might be a safer alternative to prozac and other anti-depressants as well. Too soon to call but the findings do look promising.